Clinical trials
Dry Age-related Macular Degeneration clinical trials
Below are recruiting dry age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Poway, CaliforniaAges 60 years+ - NCT06847542RecruitingPhase 3
Study of a refillable eye implant for wet AMD
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
InnsbruckAges 50 years+ - NCT07770828RecruitingPhase 3
Gene therapy for advanced dry age-related macular degeneration
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Phoenix, ArizonaAges 55 years+ - NCT06619405Recruiting
Eye Function Test for Age-Related Macular Degeneration
This study tests a quick, noninvasive eye test that measures how well you see in the dark, which can be an early sign of dry AMD. Researchers want to see if the test relates to everyday tasks like reading or driving at night.
Durham, North CarolinaAges 50–89 - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Mesa, ArizonaAges 50 years+ - NCT04627428RecruitingPhase 1/Phase 2
Stem-cell–made eye tissue transplant for dry macular degeneration
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
Beverly Hills, CaliforniaAges 55 years+ - NCT05706896Recruiting
Cord blood plasma injections for dry macular degeneration
This trial tests whether injections made from umbilical cord blood “platelet-rich plasma” can improve vision in people with dry age-related macular degeneration (AMD) in both eyes. It targets older adults with specific vision levels and no major other eye or medical problems that could affect the results.
RomeAges 65 years+ - NCT06487039RecruitingPhase 2
EB-203 for wet age-related macular degeneration
This trial tests a new medicine called EB-203 for people with wet age-related macular degeneration (AMD), a condition that causes blurry vision. It aims to see if the treatment is safe and can help improve or stabilize vision.
BusanAges 50 years+ - NCT07582042Recruiting
Vision testing in geographic atrophy treated with pegcetacoplan
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Salt Lake City, UtahAges 65–90 - NCT06536062Recruiting
Cord blood and platelet plasma for dry macular degeneration
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
Rome, RomeAges 65 years+ - NCT06351605Recruiting
Light therapy study for dry age-related macular degeneration
This study tests a light-based treatment (photobiomodulation) for dry AMD, using the Valeda Light Delivery System. It may help improve vision and eye health over time.
OsloAges Any age - NCT06165068RecruitingPhase 3
Antiplatelet and antioxidant drugs for dry AMD with drusen
This study tests whether antiplatelet drugs (like aspirin) and antioxidants can slow the growth of drusen (yellow deposits) in dry age-related macular degeneration (AMD). It may help prevent the disease from worsening.
Bangkok, DusitAges 50–85 - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Phoenix, ArizonaAges 50 years+ - NCT04339764RecruitingPhase 1/Phase 2
iPS cell eye transplant for dry macular degeneration
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
Baltimore, MarylandAges 55–95 - NCT04847635Recruiting
Laser test for aging-related macular spots under the retina
This trial studies a mild (“subthreshold”) laser treatment for reticular pseudodrusen (RPD) caused by age-related macular degeneration (AMD). If you qualify, the goal is to see whether the laser helps preserve or improve vision by targeting these specific eye changes.
GenovaAges 55 years+ - NCT05445063RecruitingPhase 1
iPSC eye-cell transplant for late dry macular degeneration
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Beijing, Beijing MunicipalityAges 50–75 - NCT05465252Recruiting
Omega-3 supplement to slow early dry macular degeneration
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
ShanghaiAges 50–85 - NCT06046118Recruiting
Light therapy for dry age-related macular degeneration
This trial tests whether a special light treatment (photobiomodulation) can help people with dry age-related macular degeneration (AMD). It is designed for those with early to moderate dry AMD who still have fairly good vision.
ParisAges 50 years+ - NCT06319872RecruitingPhase 1
Study of disulfiram for vision in retinal degeneration
This trial tests whether disulfiram, a drug used for alcohol use disorder, can improve vision in people with retinal degeneration. You must have an alcohol use diagnosis and agree to avoid alcohol for 6 months.
Rochester, New YorkAges 18 years+ - NCT06394232RecruitingPhase 1/Phase 2
Testing a cell therapy for advanced dry AMD with geographic atrophy
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Jālna, MaharashtraAges 50–100 - NCT06557460RecruitingPhase 2
Cell implant for advanced dry age-related macular degeneration
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Beverly Hills, CaliforniaAges 55–90 - NCT07158775RecruitingPhase 1/Phase 2
BS01 gene therapy for dry age-related macular degeneration
This trial tests a new gene therapy, BS01, given as an eye injection. It is for people with advanced dry age-related macular degeneration (AMD) that has caused geographic atrophy—damage to the central part of the retina. The study aims to see if the treatment is safe and can help slow vision loss.
Edison, New JerseyAges 50–85 - NCT07446582Recruiting
AI camera test for wet AMD detection
This study tests a new AI-powered camera that takes special pictures of the back of the eye to find signs of wet age-related macular degeneration (AMD) more easily. It compares images from people with wet AMD and healthy volunteers to see if the AI can spot the disease early.
Woodbridge, New JerseyAges 40 years+ - NCT07668804RecruitingPhase 1/Phase 2
Study of an eye implant for geographic atrophy from dry AMD
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
Hurstville, New South Wales (nsw)Ages 50 years+
Hear when a new Dry Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Dry Age-related Macular Degeneration trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for dry age-related macular degeneration?
- Yes. Clin2 currently lists 27 recruiting dry age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dry age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dry age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.